Overview
- The agreement values Penumbra at $374 per share, representing a premium of about 19.3% to its prior close.
- The companies expect the transaction to close in 2026, subject to customary approvals and conditions.
- Penumbra shareholders may choose $374 in cash or 3.8721 shares of Boston Scientific common stock for each Penumbra share.
- Penumbra’s portfolio centers on mechanical thrombectomy and neurovascular devices used to treat stroke, pulmonary embolism and deep vein thrombosis.
- In premarket trading, Penumbra shares jumped more than 10% as Boston Scientific fell about 4% following the before-the-open announcement.